Objective: To develop an ultra-sensitive nanoparticle contrast agent for magnetic resonance angiography (MRA), to establish a highly sensitive imaging method for complicated vascular structures, and to provide imaging evidence for precision diagnosis, treatment, prognosis, and individualized treatment of ischemic stroke. Methods: biological safety of the nano contrast agent was verified through cytotoxicity and hemolysis experiments and HE staining. Results: -enhanced MRA achieved high-resolution vascular imaging and effectively enabled the differentiation of the ischemic area, infarct core, and ischemic penumbra in an animal model of ischemic stroke. Conclusion: nanoparticles provides critical imaging evidence for the clinical diagnosis and prognosis of ischemic stroke.